<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079011</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0140/1615 - UCBG3-05</org_study_id>
    <secondary_id>2016-004360-18</secondary_id>
    <nct_id>NCT03079011</nct_id>
  </id_info>
  <brief_title>PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection</brief_title>
  <acronym>PADA-1</acronym>
  <official_title>Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, multicentric, phase III trial conducted in patients&#xD;
      receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor&#xD;
      (ER)-positive HER2-negative metastatic breast cancer and which aims to evaluate, at the onset&#xD;
      of ESR1 mutations in circulating tumor DNA, the efficacy of a change of the hormone therapy&#xD;
      (aromatase inhibitor (AI) changed to fulvestrant) combined to palbociclib, together with the&#xD;
      safety of hormone therapy and palbociclib combination in the overall population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Step 1: 1000 patients screened for circulating blood ESR1 mutation detection at regular intervals will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off (28-day cycle) + AI (letrozole, anastrozole or exemestane) administered once daily in a continuous scheme until tumor progression (assessed by RECIST) or ESR1 mutation detection&#xD;
Step 2: Up to 200 Patients with a rising circulating ESR1 mutation and without tumor progression will be randomized (1:1):&#xD;
ARM A: no change in therapy until tumor progression (RECIST) or possibility of a cross-over (step 3)&#xD;
ARM B: palbociclib 125 mg + fulvestrant 500 mg administered intramuscularly on D1,15 and 29 and once monthly thereafter until tumor progression (RECIST)&#xD;
Step 3 (cross over): up to 80 patients who have been randomized in arm A will be offered to be treated by fulvestrant + palbociclib, after having progressed under AI + palbociclib until tumor progression (RECIST) under fulvestrant + palbociclib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>Throughout study completion, up to 4 years</time_frame>
    <description>Global safety of the combination of palbociclib + endocrine therapy in the whole population, with focus on hematological toxicities.&#xD;
Safety will be assessed by the collection of grade ≥3 adverse events, using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 - in all included patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Step 2)</measure>
    <time_frame>From randomization to disease progression or death, up to 4 years</time_frame>
    <description>To assess whether a change of the hormone therapy associated with palbociclib will benefit patients for whom rising ESR1 mutations are detected during treatment with palbociclib and aromatase inhibitor.&#xD;
Progression-Free Survival (PFS) will be measured from the time of randomization to the time of tumor progression (as assessed by the investigator per RECIST v1.1) or death (whichever comes first) - in randomized patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (step 3)</measure>
    <time_frame>From cross-over, up to 4 years</time_frame>
    <description>To assess PFS in patients undergoing a cross-over following RECIST tumor progression in Arm A, from the start of crossover.&#xD;
Progression-Free Survival will be measured from the time of cross-over to the time of tumor progression (as assessed by the investigator per RECIST 1.1) or death (whichever comes first) - in all patients with crossover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (step 1&amp;2)</measure>
    <time_frame>From inclusion, up to 4 years</time_frame>
    <description>To report efficacy (PFS based on RECIST) of palbociclib combined with hormone therapy (aromatase inhibitor or fulvestrant), from the date of initial inclusion into the trial.&#xD;
Progression-Free Survival will be measured from the time of inclusion to the time of tumor progression (as assessed by the investigator per RECIST 1.1) or death (whichever comes first) - in all included patients including those who switched to fulvestrant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to strategy failure from randomization (Step 2 and 3)</measure>
    <time_frame>From randomization, up to 4 years</time_frame>
    <description>To assess whether the early switch (switch following ESR1 mutations increase) to fulvestrant contributes to a longer time to strategy failure than a late switch (cross-over following RECIST tumor progression).&#xD;
Time to strategy failure will be measured from the time of randomization until palbociclib+endocrine therapy discontinuation or death (whichever comes first) - in all randomized patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-free survival (Step 2 and 3)</measure>
    <time_frame>From randomization, up to 4 years</time_frame>
    <description>To assess whether the early switch (following ESR1 mutations increase) to fulvestrant contributes a longer chemotherapy-free survival than a late switch (cross-over following RECIST tumor progression).&#xD;
Chemotherapy-free survival will be measured from the time of randomization until the date of chemotherapy initiation or death (whichever comes first) - in all randomized patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent extra-hematological Adverse Events</measure>
    <time_frame>Throughout study completion, up to 4 years</time_frame>
    <description>To obtain additional safety data in a broad patient population treated with palbociclib and hormone therapy (aromatase inhibitor or fulvestrant) in a general Description of all extra-hematological grade ≥3 toxicities and SAEs incidence rate in the overall population and each treatment step</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by quality of life questionnaire (QLQ)-C30</measure>
    <time_frame>From inclusion and every 2 months until disease progression, up to 2 years</time_frame>
    <description>Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.&#xD;
The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other line of therapy</measure>
    <time_frame>Throughout study completion, up to 4 years</time_frame>
    <description>To report the anti-cancer treatments received after the first line therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Throughout study completion, up to 4 years</time_frame>
    <description>The overall survival is the length of time from inclusion that patients enrolled in the study are still alive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1017</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A- palbociclib + AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B- Palbociclib + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selection - Palbociclib + AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg</intervention_name>
    <description>Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle</description>
    <arm_group_label>A- palbociclib + AI</arm_group_label>
    <arm_group_label>B- Palbociclib + fulvestrant</arm_group_label>
    <arm_group_label>Selection - Palbociclib + AI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors</intervention_name>
    <description>Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)</description>
    <arm_group_label>A- palbociclib + AI</arm_group_label>
    <arm_group_label>Selection - Palbociclib + AI</arm_group_label>
    <other_name>Letrozole, Anastrozole or exemestane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant Injectable Product</intervention_name>
    <description>500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)</description>
    <arm_group_label>B- Palbociclib + fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women with proven loco-regionally recurrent or metastatic adenocarcinoma of the breast&#xD;
             not amenable to curative therapy with disease considered potentially sensitive to&#xD;
             aromatase inhibitors Note: patients relapsing while on adjuvant tamoxifen or other&#xD;
             non-aromatase inhibitor adjuvant endocrine therapy and patients relapsing more than&#xD;
             one year after the end of aromatase inhibitor adjuvant therapy are eligible for the&#xD;
             present study;&#xD;
&#xD;
          2. Age ≥18 years;&#xD;
&#xD;
          3. Life expectancy &gt;3 months;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;&#xD;
&#xD;
          5. Estrogen Receptor (ER)-positive and HER2-negative breast cancer. Where available,&#xD;
             assessment of Estrogen Receptor status should be based on the most recent tumor&#xD;
             sample; to be considered as ER-positive, the most recent breast cancer tissue examined&#xD;
             must display at least 10% of cancer cells with positive ER staining;&#xD;
&#xD;
          6. Tumor block (primary tumor or metastasis) available;&#xD;
&#xD;
          7. No prior systemic anti-cancer therapy for metastatic or advanced disease&#xD;
             (chemotherapy, targeted therapy or hormone therapy); prior initiation of LHRH agonist&#xD;
             or bone-directed agents is however allowed);&#xD;
&#xD;
          8. Menopausal patients or patients with suppressed ovarian function&#xD;
&#xD;
               -  Women with bilateral oophorectomy&#xD;
&#xD;
               -  Postmenopausal women, as defined by any of the following criteria:&#xD;
&#xD;
                    -  Age 60 or over;&#xD;
&#xD;
                    -  Age 50 to 59 years and meets one of the following criteria:&#xD;
&#xD;
                         -  Amenorrhea for ≥24 months and follicle-stimulating hormone within the&#xD;
                            postmenopausal range;&#xD;
&#xD;
                         -  patients with hysterectomy or chemotherapy-induced amenorrhea must&#xD;
                            display follicle-stimulating hormone within the postmenopausal range;&#xD;
&#xD;
               -  Other women, provided they are being treated with monthly LHRH analogues (first&#xD;
                  injection performed ≥7 days before the treatment initiation) and are willing to&#xD;
                  continue to receive LHRH agonist therapy for the duration of the trial;&#xD;
&#xD;
          9. Patients may have measurable (according to Response Evaluation Criterion in Solid&#xD;
             Tumors (RECIST v1.1) or not measurable disease&#xD;
&#xD;
               -  Patients with only blastic bone lesions are not eligible;&#xD;
&#xD;
               -  Patients with only pleural, cardiac or peritoneal effusion or meningeal&#xD;
                  carcinomatosis are not eligible;&#xD;
&#xD;
         10. Adequate organ and marrow function as defined below:&#xD;
&#xD;
               -  Hemoglobin ≥90 g/L&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 g/L&#xD;
&#xD;
               -  Platelet count ≥100 g/L&#xD;
&#xD;
               -  Serum bilirubin ≤1.5 × upper limit of normal (ULN). This will not apply to&#xD;
                  patients with confirmed Gilbert's syndrome.&#xD;
&#xD;
               -  ALT and AST ≤3 × ULN;&#xD;
&#xD;
               -  Alkaline phosphatase ≤2.5 x ULN (≤5.0 x ULN if bone or liver metastases present)&#xD;
&#xD;
               -  Serum creatinine ≤1.5 × ULN or calculated creatinine clearance ≥ 60 mL/min as&#xD;
                  determined by Cockcroft-Gault (using actual body weight) formula for females&#xD;
                  [creatinine clearance =Weight (kg) × (140 - Age) × 0.85 (mL/min)/ (72 × serum&#xD;
                  creatinine (mg/dL))&#xD;
&#xD;
         11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and any protocol-related procedures including screening evaluations;&#xD;
&#xD;
         12. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical&#xD;
             procedures to NCI CTCAE version 4.03 Grade 1 (except alopecia or other toxicities not&#xD;
             considered a safety risk for the patient at investigator's discretion);&#xD;
&#xD;
         13. Written informed consent obtained prior to performing any protocol-related procedures&#xD;
             including screening evaluations;&#xD;
&#xD;
         14. Patient affiliated to a social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Locally advanced breast cancer or loco-regional relapse amenable for any treatment&#xD;
             with curative intent;&#xD;
&#xD;
          2. Her2-positive or equivocal tumor status either on the primary or on the recurrent&#xD;
             tumor, defined as IHC3+, Fish/Cish amplified or Fish/Cish equivocal according to the&#xD;
             ASCO2015 criteria;&#xD;
&#xD;
          3. Prior endocrine therapy in the metastatic setting is not allowed;&#xD;
&#xD;
          4. Prior treatment with any CDK 4/6 inhibitor in the adjuvant or metastatic setting&#xD;
             (neoadjuvant/preoperative treatment is allowed); however, prior therapy with another&#xD;
             targeted treatment in the adjuvant setting is allowed;&#xD;
&#xD;
          5. Visceral crisis: Advanced, symptomatic, visceral spread that is at risk of&#xD;
             life-threatening complication in the short term and that requires chemotherapy;&#xD;
&#xD;
          6. Any major surgery (defined as requiring general anaesthesia) or significant traumatic&#xD;
             injury within 4 weeks of treatment initiation or patients that may require major&#xD;
             surgery during the course of the study; however, surgical diagnostic procedure is&#xD;
             allowed (even if performed under general anaesthesia);&#xD;
&#xD;
          7. Known, active bleeding diathesis;&#xD;
&#xD;
          8. Any serious known concomitant systemic disorder (e.g. known active infection including&#xD;
             HIV, or cardiac disease) incompatible with the study (at the discretion of&#xD;
             investigator), previous history of bleeding diathesis, or anti-coagulation treatment&#xD;
             (the use of low molecular weight heparin is allowed);&#xD;
&#xD;
          9. Patients unable to swallow tablets;&#xD;
&#xD;
         10. History of mal-absorption syndrome or other condition that would interfere with&#xD;
             enteral absorption;&#xD;
&#xD;
         11. Chronic daily treatment with corticosteroids with a dose of ≥10 mg/day&#xD;
             methylprednisolone equivalent (excluding inhaled steroids);&#xD;
&#xD;
         12. Known active uncontrolled or symptomatic central nervous system (CNS) metastases,&#xD;
             carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,&#xD;
             cerebral oedema, and/or progressive growth. Patients with a history of CNS metastases&#xD;
             or cord compression are eligible if they have been definitively treated with local&#xD;
             therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off&#xD;
             anticonvulsants and steroids for at least 4 weeks before treatment start;&#xD;
&#xD;
         13. Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant, palbociclib&#xD;
             or any of their excipients;&#xD;
&#xD;
         14. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging&#xD;
             drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia);&#xD;
&#xD;
         15. Patients treated within the last 7 days prior to treatment start in the trial with&#xD;
             drug that are known to be CYP3A4 inhibitors, drugs that are known to be CIP3A4&#xD;
             inducers, who underwent a grapefruit cure;&#xD;
&#xD;
         16. Patients already included in another therapeutic trial evaluating an investigational&#xD;
             medicinal product or having received an investigational medicinal product within 3&#xD;
             months;&#xD;
&#xD;
         17. History of previous:&#xD;
&#xD;
               -  Any other stage II, III, IV cancer within 5 years preceding patient enrollment in&#xD;
                  the trial - however, multiple primary breast cancers (controlateral/ipsilateral&#xD;
                  cancers/local relapses) are allowed pending all tumor masses were ER+;&#xD;
&#xD;
               -  Any history of hematological malignancy;&#xD;
&#xD;
         18. Persons deprived of their freedom or under guardianship or incapable of giving&#xD;
             consent;&#xD;
&#xD;
         19. Pregnancy or lactation period. Women of childbearing potential must implement adequate&#xD;
             non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive&#xD;
             devices, sterilization; LHRH agonist cannot be considered as an efficient&#xD;
             contraceptive measure) during study treatment and for 90 days after discontinuation. A&#xD;
             serum pregnancy test must be negative in premenopausal women or women with amenorrhea&#xD;
             of less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François-Clément BIDARD, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzette DELALOGE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Claire HARDY BESSARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Armoricain d'Oncologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Auxerre</name>
      <address>
        <city>Auxerre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli Ducos</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de boulogne sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg En Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique PASTEUR-CFRO</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Cergy - Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipole de Savoie</name>
      <address>
        <city>Challes Les Eaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hôpital Sainte Marie</name>
      <address>
        <city>Chalon-sur-saone</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH William Morey</name>
      <address>
        <city>Chalon-sur-saone</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Métropole de Savoie</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Fréjus St-Raphaël</name>
      <address>
        <city>Frejus</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard - Groupe Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental de Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Cap d'Or</name>
      <address>
        <city>La Seyne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois-perret</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique François Chénieux</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie radiothérapie de Macon</name>
      <address>
        <city>Macon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier ANNECY GENEVOIS</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Montceau les mines</name>
      <address>
        <city>Montceau-les-mines</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre ONCOGARD - Institut de Cancérologie du Gard</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Diaconesses-Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>PAU</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi</name>
      <address>
        <city>Plerin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Croix du Sud</name>
      <address>
        <city>Quint Fonsegrives</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de radiothérapie et d'oncologie médicale LE-CROME</name>
      <address>
        <city>Ris Orangis</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Gregoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie lucien Neuwith</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Broussais</name>
      <address>
        <city>Saint-malo</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-nazaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Stauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-Bains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tours - Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNEOS Site Hôpital Robert Schuman</name>
      <address>
        <city>Vantoux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESR1 mutation detection, ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

